Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Signal transduction by lymphocyte antigen receptors

1994 • 2,145 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

Human tumor antigens recognized by T lymphocytes.

1996 • 860 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Rapid Effector Function in CD8+ Memory T Cells

1997 • 652 citations

Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

1998 • 534 citations

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1999 • 499 citations

Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues

1998 • 487 citations

Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors

1997 • 432 citations

Cancer vaccines

1998 • 422 citations

Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.

1993 • 385 citations

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

1995 • 296 citations

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.

1998 • 238 citations

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

1999 • 223 citations

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1998 • 222 citations

Alterations in the signal‐transducing molecules of T cells and nk cells in colorectal tumor‐infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease

1995 • 217 citations

Tumor antigen presentation by murine epidermal cells.

1991 • 211 citations

Alterations in T cell receptor and signal transduction molecules in melanoma patients.

1995 • 192 citations

A sensitive ELISPOT assay to detect low-frequency human T lymphocytes

1997 • 170 citations

Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.

1996 • 169 citations

Where have all the T cells gone? Mechanisms of immune evasion by tumors

1999 • 153 citations

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.

1997 • 124 citations

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

1998 • 112 citations

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28

1996 • 93 citations

HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients

1998 • 86 citations

MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.

1999 • 82 citations

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28

1996 • 71 citations

Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine

1997 • 65 citations

In situ T cells in melanoma

1999 • 59 citations

Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma

1997 • 40 citations

Tumor Infiltrating Lymphocytes in Melanoma Comprise High Numbers of T-Cell Clonotypes That Are Lost during in Vitro Culture

2000 • 25 citations